research Modulation of glucocorticoid action and the treatment of type-2 diabetes
Targeting glucocorticoid action might help treat type-2 diabetes, but human trials are needed.
Search
for
Sort by
Research
180-210 / 1000+ results research GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling
GLP-1 therapies, especially semaglutide and tirzepatide, may cause hair loss, particularly in women and with rapid weight loss.
research Increased Insulin Sensitivity by Metformin Enhances Intense-Pulsed-Light-Assisted Hair Removal in Patients with Polycystic Ovary Syndrome
Taking metformin with intense pulsed light therapy improves hair removal for women with PCOS.
research Tata Laksana Hipoglikemia pada Pasien Diabetes
Hypoglycemia in diabetes needs quick treatment to prevent serious health issues.
research Selected abstracts from the 47th meeting of the Irish Endocrine Society Sligo, 24th & 25th November 2023
Continuous glucose monitoring and GLP-1 receptor agonists improve diabetes management, but personalized care and education are crucial.
research THU372 Finasteride Induced Hyperglycemia
Finasteride may worsen blood sugar control in diabetic patients.
research Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity
Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.
research Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance
Metformin helps with PCOS symptoms no matter the patient's initial insulin resistance or weight.
research Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: A randomized, double-blind, and placebo control trial
Metformin combined with lifestyle changes improves insulin resistance and reduces testosterone levels in women with PCOS more than lifestyle changes alone.
research Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
Newer GLP-1 drugs like semaglutide may cause hair loss.
research Circulating sex hormone binding globulin levels are modified with intensive lifestyle intervention, but their changes did not independently predict diabetes risk in the Diabetes Prevention Program
Changes in SHBG levels don't predict diabetes risk reduction.
research Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face”
The study involving 1,226 participants examined the dermatologic effects of weight management treatments, particularly glucagon-like peptide 1-receptor agonists (GLP-1RAs). It found that greater weight loss was associated with increased reports of negative aesthetic impacts such as skin sagging, facial volume loss, and hair shedding. Specifically, among those losing more than 20% of body weight, 72% reported skin sagging and 52% reported hair loss. However, improvements were noted in preexisting inflammatory and hormonally driven skin conditions like hidradenitis suppurativa and acanthosis nigricans. The findings highlight the need for further research into the mechanisms and incidence of these outcomes with GLP-1RA treatments.
research GLP‐1 agonists and hair loss: a call for further investigation
More research is needed to understand if GLP-1 agonists affect hair health.
research Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report
A rash from semaglutide may be due to propylene glycol, not the drug itself.
research The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?
GLP-1 receptor agonists may help or harm hair health, needing more research.
research GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms
GLP-1 receptor agonists may increase the risk of hair loss, especially non-scarring types, due to weight loss-related nutrient deficiencies.
research When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?
Metformin should be used for PCOS mainly in those with glucose intolerance, and has limited benefits for infertility or hirsutism.
research Evaluation of Insulin Resistance Markers in Polycystic Ovary Syndrome Patients Receiving Metformin, Finasteride or Both
Metformin reduces insulin resistance in PCOS, but combining it with finasteride offers extra benefits.
research Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms
GLP-1 receptor agonists increase the risk of hair loss, mainly due to weight loss-related nutrient deficiency.
research Metabolic complications of glucocorticoids – Prevention by metformin
Metformin can help prevent the side effects of glucocorticoid medications on metabolism.
research Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights
Semaglutide is an effective weekly treatment for obesity, promoting weight loss and improving health, despite some side effects.
research Does finasteride, as well as metformin, improve insulin resistance in PCOS?
Both finasteride and metformin effectively treat PCOS by reducing hormone levels and insulin resistance.
research Chromium supplementation in women with polycystic ovary syndrome: Systematic review and meta-analysis
Chromium supplements don't improve insulin, hormone levels, or cholesterol in women with PCOS but raise testosterone levels.
research Effects of Low-Dose Spironolactone Combined with Metformin or Either Drug Alone on Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Pilot Study
Combining spironolactone with metformin reduces insulin resistance in PCOS better than either drug alone.
research Teneligliptin-induced hair loss: A case report
Increasing Teneligliptin on his own caused a man's hair loss, which stopped when he ceased the medication.
research Glibenclamide reverses cromakalim-induced anti-ischemic effect in conscious rabbits
research 0439 Temporal–phenotype signatures of alopecia associated with GLP-1–based therapies: A PRISMA-ScR scoping review
GLP-1 therapies can cause hair loss, but hair often regrows after stopping or reducing the drug.
research Mitigating GLP-1–Related Dermatologic Adverse Effects through Methylene Blue’s Antioxidant Action
Methylene blue, combined with ceramides, may reduce skin and hair side effects from GLP-1 therapy.
research Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes Mellitus
Glycemic control medications for Type 2 diabetes can affect skin conditions like psoriasis.
research Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome.
Insulin changes sex hormone levels in women with polycystic ovary syndrome without affecting other hormone releases.